NEW YORK (GenomeWeb News) – Myriad Genetics and Janssen Research & Development today announced they will use Myriad's BRACAnalysis test in a Phase III clinical trial for Yondelis (trabectedin).

Janssen is developing Yondelis as a treatment for advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancers. The firm is studying the drug in combination with a chemo regimen in the third-line setting comparing it against just chemotherapy in patients who have had two previous lines of platinum-based chemo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.